BRAF V600 mutation
2 drugsPredictive biomarker for patient selection in 6 indications
2
Approved Drugs
6
Indications
1
Companies
BRAF V600 mutation is a precision-medicine biomarker linked to 2 FDA-approved targeted drugs from 1 company, spanning 6 indications including Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Hepatocellular Carcinoma. Explore the targeted therapies, indications, testing methods, and companies developing BRAF V600 mutation drugs below.
Search BRAF V600 mutation Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting BRAF V600 mutation
| Drug | Company | Therapeutic Area |
|---|---|---|
| TECENTRIQ | Roche | Oncology |
| TECENTRIQ HYBREZA | Roche | Oncology |
BRAF V600 mutation Indications
Non-Small Cell Lung Cancer Small Cell Lung Cancer Hepatocellular Carcinoma Melanoma Alveolar Soft Part Sarcoma Muscle Invasive Bladder Cancer